Cargando…
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in term...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890326/ https://www.ncbi.nlm.nih.gov/pubmed/27255529 http://dx.doi.org/10.1186/s13075-016-1022-1 |